Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer's disease: a comprehensive review of the characteristics and therapeutic strategies
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Dual-targeting therapies inhibiting amyloid beta (Aβ) and tau aggregation show promise for Alzheimer's disease (AD). Targeting specific domains offers a new strategy for effective AD drug development.
Area Of Science
- Neuroscience
- Biochemistry
- Pharmacology
Background
- Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid beta (Aβ) and tau pathology.
- Accumulated Aβ and tau aggregates exert neurotoxic effects, driving neurodegeneration and memory loss in AD patients.
Purpose Of The Study
- To review therapeutic strategies targeting both Aβ and tau aggregation and dissociation.
- To explore agents that simultaneously regulate Aβ and tau pathology for improved AD treatment.
Main Methods
- Identification of specific amino acid domains involved in Aβ and tau aggregation/dissociation.
- Review of therapeutic agents targeting these domains to inhibit or promote aggregate dissociation.
Main Results
- Dual inhibitors targeting both Aβ and tau aggregation/dissociation have been investigated.
- Specific domains crucial for Aβ and tau aggregation have been identified, guiding therapeutic agent development.
Conclusions
- Simultaneous dual inhibition or dissociation of Aβ and tau aggregates represents a promising therapeutic avenue for AD.
- This review facilitates the design of next-generation dual-targeting drugs for more effective Alzheimer's disease treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...